TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02471950

Intervention type: PROCEDURE
Intervention: 2.5 % Isoflurane administration
Description: Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
Study: NCT02354781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1.CMV.huFollistin344
Description: Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
Study: NCT03082950

Intervention type: DIAGNOSTIC_TEST
Intervention: polymerase chain reaction
Description: PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.

Intervention type: DIAGNOSTIC_TEST
Intervention: polymerase chain reaction
Description: PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
Study: NCT04269005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of the SCCM
Description: Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
Study: NCT02761486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325mg aspirin per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo in matching capsules
Study: NCT00427089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate
Description: 2L gut lavage solution
Study: NCT02941601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study: NCT00427089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Phosphate solution (NaP)
Description: 45 ml solution; BID
Study: NCT00448435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW815SF HFA MDI
Description: salmeterol and fluticasone propionate combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW815SF HFA MDI
Description: salmeterol and fluticasone propionate combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW815SF HFA MDI
Description: salmeterol and fluticasone propionate combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol and fluticasone propionate
Description: salmeterol + fluticasone propionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol and fluticasone propionate
Description: salmeterol + fluticasone propionate
Study: NCT01839721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifilact®
Description: placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifilact®
Description: placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02119754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plurogel PN
Study: NCT03351881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Description of Organ Donation Policy
Description: Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Description of Organ Donation Policy
Description: Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Description of Organ Donation Policy
Description: Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
Study: NCT02615704

Intervention type: DEVICE
Intervention: Active group with MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS

Intervention type: DEVICE
Intervention: Active group without MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS

Intervention type: DEVICE
Intervention: Control group with MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS

Intervention type: DEVICE
Intervention: Control group without MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
Study: NCT04088383

Intervention type: OTHER
Group type: OTHER
Intervention: Amnios™ RT
Description: Acellular human allograft

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline
Study: NCT02232620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Study: NCT02830997

Intervention type: DEVICE
Intervention: Stereotactic guidance system
Study: NCT02231021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alogliptin
Description: alogliptin 25 mg add-on background medication metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg add-on background medication metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alogliptin + pioglitazone
Description: alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
Study: NCT01481623

Intervention type: OTHER
Group type: OTHER
Intervention: Constitution of a biological bank
Description: Blood samples for the constitution of a biobank (DNA, RNA, serum)

Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic studies
Description: oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
Study: NCT04199234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product consumption
Description: Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator product consumption (Iron sulphate)
Description: Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
Study: NCT04621396

Intervention type: OTHER
Intervention: Observational screening study
Study: NCT04693260

Intervention type: DEVICE
Group type: OTHER
Intervention: Visual Acuity with a Hand-held Device Supported by Mobile App.
Description: The Insight will be compared to a standard ETDRS eyechart
Study: NCT02684513

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Carbohydrate Beverage
Description: The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rehydration beverage
Description: The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
Study: NCT00037869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131 Metaiodobenzylguanidine
Study: NCT01978353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training
Description: Participants receive memory training to facilitate learning and memory of face-name associations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants receive information about memory functioning and aging
Study: NCT03984903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Learning of Exercises
Description: Patients learn exercise from multimedia content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Learning of Exercises
Description: Physiotherapist teach exercises to patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Patients do at least 20 minutes motor control exercise in a day at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Patients do at least 20 minutes motor control exercise in a day at home.
Study: NCT00331123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
Study: NCT02941601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study: NCT02015637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: single dose
Study: NCT01100801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 with cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 with oxaliplatin
Study: NCT02641782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibody ch14.18
Description: 17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibody ch14.18
Description: 17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: 250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
Study: NCT00331123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo patch,changed every 3-4 days for 24 weeks during double blind phase
Study: NCT01052896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 300mg po TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-alike of gabapentin 300mg given po tid
Study: NCT02761551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder notifications via autodialer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder notifications via autodialer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder notifications via autodialer
Study: NCT04029116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: 150 mg every 72 hours for 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole Tablet
Description: 150 mg every 72 hours for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBREXAFUNGERP
Description: 300 mg BID (one day) every 4 weeks for a total of 6 dosing days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: BID (one day) every 4 weeks for a total of 6 dosing days
Study: NCT01672034

Intervention type: PROCEDURE
Intervention: Laparoscopic gastric bypass surgery
Study: NCT03606980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone sodium phosphate administered via iontophoresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Iontophoresis on affected knee
Study: NCT02641782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2 i.v.
Description: 3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 s.c.
Description: 0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
Study: NCT03606980

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoresis
Description: Iontophoresis on affected knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy of affected knee
Study: NCT02641782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: 160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinoic acid
Description: 160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
Study: NCT03606980

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy of affected knee

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy of affected knee
Study: NCT04084964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-hospitalisation platform for heart failure
Description: The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
Study: NCT01961661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months
Study: NCT00524849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zometa 1 mg weekly (intravenous)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zometa 4 mg every four weeks (intravenous)
Study: NCT03107871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simple Syrup
Description: Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
Study: NCT04195165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX
Description: The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX
Description: The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
Study: NCT01493908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High price
Description: Acetaminophen label as high price

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low price
Description: Acetaminophen label as low price

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low price participants aware paying part
Description: Acetaminophen label as low price; participants aware they are paying part of the full price

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No price
Description: acetaminophen. No price - price issue not introduced to participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Free of charge
Description: Acetaminophen. participants aware the product is free of charge
Study: NCT01316653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW Healthier
Description: Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW Smarter
Description: Group sessions that meet six times over the course of three years with quarterly newsletters.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GROW Smarter
Description: Group sessions that meet six times over the course of three years with quarterly newsletters.
Study: NCT00936286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpiroTiger
Description: Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
Study: NCT04467203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadanafil
Description: Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadanafil
Description: Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting
Study: NCT01532986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated care management for Parkinson's disease
Description: Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.

Intervention type: OTHER
Group type: OTHER
Intervention: Coordinated care management for Parkinson's disease
Description: Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational handout
Description: To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise.
Study: NCT03303976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioconjugate pneumococcal vaccine
Description: Bioconjuagte vaccine against bacterial pneumococcal infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioconjugate pneumococcal vaccine
Description: Bioconjuagte vaccine against bacterial pneumococcal infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioconjugate pneumococcal vaccine
Description: Bioconjuagte vaccine against bacterial pneumococcal infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Multivalent plain polysaccharide vaccine
Description: Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
Study: NCT02604394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rheolytic Thrombectomy
Description: RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~1. The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~2. The disposable pump connects to a bag of heparinized saline.~3. The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional PCI
Description: In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
Study: NCT03272763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Toffee mask
Description: Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
Study: NCT04458103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous RVAD
Description: ProtekDuo or Impella RP
Study: NCT01458704

Intervention type: OTHER
Intervention: next generation sequencing
Description: next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
Study: NCT03079232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCTAV Patient
Description: In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCTAV Control group
Description: In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.